Compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-12528825-B2
Application number	US-202117795985-A
Country	US
Kind code	B2
Filing date	Jan 29, 2021
Priority date	Jan 29, 2020
Publication date	Jan 20, 2026
Grant date	Jan 20, 2026

Abstract

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

First claim

The invention claimed is:

1 . A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

3 . A method of inhibiting the level and/or activity of BRD9 in a cell, the method involving contacting the cell with an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

4 . The method of claim 3 wherein the cell is a cancer cell.

5 . The method of claim 4 , wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.

6 . The method of claim 5 , wherein the cancer is a sarcoma.

7 . The method of claim 6 , wherein the sarcoma is a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, or low-grade rhabdomyosarcoma.

8 . The method of claim 7 , wherein the sarcoma is synovial sarcoma.

9 . A method of treating a BAF complex-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

10 . A method of treating an SS18-SSX fusion protein-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

11 . A method of treating a BRD9-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

12 . The method of claim 9 , wherein the disorder is cancer or an infection.

13 . A method of treating a cancer in a subject in need thereof, the method including administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

14 . The method of claim 13 , wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.

15 . The method of claim 14 , wherein the cancer is a sarcoma.

16 . The method of claim 15 , wherein the sarcoma is a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, or low-grade rhabdomyosarcoma.

17 . The method of claim 16 , wherein the sarcoma is synovial sarcoma.

18 . A method of treating infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignees

• Foghorn Therapeutics Inc

Inventors

• Ruppel Sabine K
• Yang Zhaoxia
• Lowe Jason T
• Voigt Johannes H

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• C07D495/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/4545 Primary

  containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title